Galantamine Hydrobromide Solution
Product Images NDC 0054-0137

26 FDA label images from Hikma Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Galantamine Hydrobromide (NDC 0054-0137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of Galantamine Hydrobromide, depicting the molecular arrangement including aromatic rings, oxygen and nitrogen atoms, and the hydrobromide (HBr) group.*
FDA Label Image

Figure 1 (Gal Figure 1)

Figure 1 (Gal Figure 1)
A line graph showing the mean change from baseline in ADAS-cog score over 21 weeks of treatment comparing placebo and Galantamine Hydrobromide at doses of 8 mg/day, 16 mg/day, and 24 mg/day. Improvement and decline in cognitive function are indicated on the vertical axis, with different lines representing each treatment group.*
FDA Label Image

Figure 2 (Gal Figure 2)

Figure 2 (Gal Figure 2)
A cumulative percentage graph showing ADAS-cog change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares placebo and three doses of Galantamine Hydrobromide (8 mg/day, 16 mg/day, 24 mg/day), illustrating patient distribution across cognitive change categories, including negative changes and no change.*
FDA Label Image

Figure 3 (Gal Figure 3)

Figure 3 (Gal Figure 3)
A bar chart showing the percentage of patients categorized by CIBIC-plus rating from markedly improved to markedly worse. The chart compares placebo, 8 mg/day, 16 mg/day, and 24 mg/day dosage groups of Galantamine Hydrobromide oral solution, illustrating the distribution of patient outcomes across different treatment doses.*
FDA Label Image

Figure 4 (Gal Figure 4)

Figure 4 (Gal Figure 4)
A line graph showing the mean change from baseline in ADAS-cog scores over 26 weeks of treatment. The graph plots three groups: placebo, 24 mg/day, and 32 mg/day, indicating cognitive improvement or decline on the vertical axis and weeks of treatment on the horizontal axis. The 24 mg/day and 32 mg/day groups show improvement compared to placebo, which shows decline over time.*
FDA Label Image

Figure 5 (Gal Figure 5)

Figure 5 (Gal Figure 5)
A cumulative percentage plot depicting the ADAS-cog change from baseline in patients for Galantamine Hydrobromide. The graph compares placebo and two dosage groups: 24 mg/day and 32 mg/day. The X-axis represents the ADAS-cog change from baseline, ranging from -15 to 15 points, while the Y-axis shows the cumulative percentage of patients from 0 to 100%. Vertical lines denote specific ADAS-cog score changes at -10, -7, -4 points and no change.*
FDA Label Image

Figure 6 (Gal Figure 6)

Figure 6 (Gal Figure 6)
A bar chart illustrating patient distribution by CIBIC-plus Rating for Galantamine Hydrobromide oral solution groups: Placebo, 24 mg/day, and 32 mg/day. The chart shows the percentage of patients across categories from Markedly Improved to Markedly Worse, highlighting variations in patient outcomes across dosing groups.*
FDA Label Image

Figure 7 (Gal Figure 7)

Figure 7 (Gal Figure 7)
A line graph depicting the mean change from baseline in ADAS-cog scores over 26 weeks of treatment. The x-axis represents weeks of treatment (0, 3, 13, 26), and the y-axis shows mean change with improvement upward and decline downward. Three groups are shown: placebo (decline over time), 24 mg/day, and 32 mg/day doses (both showing improvement followed by slight decline). Error bars indicate the standard error of the mean.*
FDA Label Image

Figure 8 (Gal Figure 8)

Figure 8 (Gal Figure 8)
A cumulative percentage curve chart depicting ADAS-cog change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares three groups: placebo, 24 mg/day, and 32 mg/day doses, showing patient distribution across cognitive score changes over a range from -15 to +15 points.*
FDA Label Image

Figure 9 (Gal Figure 9)

Figure 9 (Gal Figure 9)
A bar chart depicting percentage of patients on the CIBIC-plus rating scale comparing Placebo, 24 mg/day, and 32 mg/day doses. Categories on the x-axis range from Markedly Improved to Markedly Worse, showing distributions of patient outcomes across these groups.*
FDA Label Image

Figure 10 (Gal Figure 10)

Figure 10 (Gal Figure 10)
This line graph shows the mean change from baseline in ADAS-cog scores over 13 weeks of treatment, comparing placebo and 24 mg/day doses. The y-axis represents mean change (±SE), with improvement indicated upward and decline downward. The x-axis represents weeks of treatment at 0, 4, and 13 weeks. The 24 mg/day group shows improvement that plateaus after 4 weeks, while placebo shows slight decline by week 13.*
FDA Label Image

Figure 11 (Gal Figure 11)

Figure 11 (Gal Figure 11)
A cumulative distribution plot showing the percentage of patients versus ADAS-cog change from baseline. The graph compares placebo and treatment with 24 mg or 32 mg per day, with vertical markers at -10, -7, -4 points, and no change, depicting cognitive score changes over the study period.*
FDA Label Image

Figure 12 (Gal Figure 12)

Figure 12 (Gal Figure 12)
A bar chart comparing the percentage of patients by CIBIC-plus Rating categories between Placebo and 24 mg or 32 mg/day dosages. The x-axis lists categories from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients. Bars represent patient distribution across ratings for both treatment groups.*
FDA Label Image

Instruction Figure 1 (Patient Figure 1)

Instruction Figure 1 (Patient Figure 1)
An instructional illustration showing two hands opening a bottle. One hand grips the bottle while the other hand presses down on the cap to twist it open. This diagram likely demonstrates how to open the Galantamine Hydrobromide oral solution bottle safely.*
FDA Label Image

Instruction Figure 2 (Patient Figure 2)

Instruction Figure 2 (Patient Figure 2)
An instructional illustration showing a hand holding a bottle while another hand inserts a dropper or measuring device into the bottle's opening, likely demonstrating proper use or dosing of an oral solution.*
FDA Label Image

Instruction Figure 3a (Patient Figure 3a)

Instruction Figure 3a (Patient Figure 3a)
An instructional illustration showing a hand holding an oral dosing syringe while another hand is gently squeezing a bottle to fill the syringe with liquid medication. The image demonstrates the correct technique for measuring a liquid dose from a bottle, commonly used for oral solutions like Galantamine Hydrobromide 4 mg/mL.*
FDA Label Image

Instruction Figure 3b (Patient Figure 3b)

Instruction Figure 3b (Patient Figure 3b)
An instructional line drawing showing a person holding an oral medication bottle upside down with one hand while the other hand holds a measuring syringe, drawing liquid from the bottle into the syringe. This illustrates the process of measuring a dose of liquid medication for oral administration.*
FDA Label Image

Instruction Figure 4a (Patient Figure 4a)

Instruction Figure 4a (Patient Figure 4a)
An instructional illustration showing two hands: one holding a bottle upright, the other using a syringe to extract liquid from the bottle. This image likely demonstrates the proper technique for withdrawing oral solution medication from its bottle using a syringe.*
FDA Label Image

Instruction Figure 4b (Patient Figure 4b)

Instruction Figure 4b (Patient Figure 4b)
An instructional illustration showing two hands, one holding an oral solution bottle upright and the other inserting a syringe into the bottle's opening, likely demonstrating how to draw medication from the bottle using the syringe.*
FDA Label Image

Instruction Figure 5a (Patient Figure 5a)

Instruction Figure 5a (Patient Figure 5a)
An instructional illustration showing a hand holding an oral dosing syringe above a cup, with a second hand holding the cup steady. The image demonstrates how to draw liquid medication into the syringe for oral administration.*
FDA Label Image

Instruction Figure 5b (Patient Figure 5b)

Instruction Figure 5b (Patient Figure 5b)
A black and white line drawing illustrating the administration of an oral solution. One hand holds a cup, while the other hand holds a syringe poised above the cup, demonstrating how to measure or dispense the solution for oral use.*
FDA Label Image

Instruction Figure 6 (Patient Figure 6)

Instruction Figure 6 (Patient Figure 6)
Illustration showing a hand holding a cup while another hand stirs its contents with a spoon or stirrer. The image appears instructional, likely demonstrating how to mix or prepare an oral solution.*
FDA Label Image

Instruction Figure 7 (Patient Figure 7)

Instruction Figure 7 (Patient Figure 7)
An instructional illustration showing a pair of hands opening a bottle by twisting off the cap. The image demonstrates proper hand positioning for opening the bottle cap.*
FDA Label Image

Instruction Figure 8a (Patient Figure 8a)

Instruction Figure 8a (Patient Figure 8a)
Illustration showing hands stirring a liquid in a cup with a stick or spoon. The image appears to depict preparation or mixing instructions, possibly for an oral solution product like Galantamine Hydrobromide 4 mg/mL.*
FDA Label Image

Instruction Figure 8b (Patient Figure 8b)

Instruction Figure 8b (Patient Figure 8b)
An instructional line drawing showing a hand holding a measuring syringe or dropper above a small cup. The illustration appears to demonstrate the method of dispensing oral solution medication into a cup for dosing.*
FDA Label Image

100 mL Bottle Label (Bottle Label)

100 mL Bottle Label (Bottle Label)
Label of Galantamine Oral Solution USP 4 mg/mL, 100 mL bottle, from Hikma Pharmaceuticals USA Inc. The label states the concentration, dispensing, and storage instructions, the product NDC (0054-0137-49), and warnings to keep out of reach of children and not to freeze. It includes a barcode and space for lot number and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.